Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bristol-Myers Squibb Company
FDA approves Glucophage XR 750 mg tablets
May 14th, 2003
Bristol-Myers Squibb Company (BMY) announced that the U.S. Food and Drug Administration (FDA) has approved Glucophage XR (metformin HCl extended release tablets) 750 mg tablet, a new dosage strength of one of the leading type 2 diabetes therapies. Glucophage XR, which was launched in October 2000, is a once-daily dosage form of Glucophage (metformin hydrochloride tablets). Glucophage XR 750 mg was developed to provide physicians with an additional option to make titration to higher doses more convenient, when needed and appropriate. Glucophage XR is already available in a 500 mg strength and is approved together with diet and exercise for use as...
Source: Biotech Week (2003-05-14)
|
